T M Bocan

Summary

Affiliation: Parke-Davis Pharmaceutical Research
Country: USA

Publications

  1. ncbi The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits
    T M Bocan
    Departments of Cardiovascular Therapeutics, Parke Davis Pharmaceutical Research, Division of Warner Lambert, 2800 Plymouth Rd, Ann Arbor, MI 48105, USA
    Arterioscler Thromb Vasc Biol 20:70-9. 2000
  2. ncbi Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure
    J T Peterson
    Departments of Cardiovascular Pharmacology, Pfizer Global Research and Development, Ann Arbor, Michigan, USA
    Circulation 103:2303-9. 2001
  3. ncbi A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit
    T M Bocan
    Department of Vascular and Cardiac Diseases, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, MI 48105, USA
    Atherosclerosis 136:203-16. 1998
  4. ncbi The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression
    T M Bocan
    Department of Cardiovascular Therapeutics, Pfizer Global Research and Development, Ann Arbor Laboratories, Pfizer Inc, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Atherosclerosis 157:97-105. 2001
  5. ncbi HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit
    T M Bocan
    Department of Vascular and Cardiac Diseases, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, MI 48105, USA
    Atherosclerosis 139:21-30. 1998
  6. ncbi Molecular sieving and mass spectroscopy reveal enhanced collagen degradation in rabbit atheroma
    J Chen
    Department of Cardiovascular Therapeutics, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Atherosclerosis 159:289-95. 2001
  7. ncbi Toxicologic effects of a novel acyl-CoA:cholesterol acyltransferase inhibitor in cynomolgus monkeys
    J F Reindel
    Department of Pathology, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, Michigan 48105
    Toxicol Pathol 22:510-8. 1994
  8. ncbi MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition
    H Li
    Department of Cardiovascular Therapeutics, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Cardiovasc Res 46:298-306. 2000
  9. ncbi Recombinant adenovirus vector mediated expression of lipoprotein (a) [Lp(a)] in rabbit plasma
    R Ramharack
    Department of Cardiovascular Therapeutics, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Biochim Biophys Acta 1438:322-8. 1999

Collaborators

Detail Information

Publications9

  1. ncbi The ACAT inhibitor avasimibe reduces macrophages and matrix metalloproteinase expression in atherosclerotic lesions of hypercholesterolemic rabbits
    T M Bocan
    Departments of Cardiovascular Therapeutics, Parke Davis Pharmaceutical Research, Division of Warner Lambert, 2800 Plymouth Rd, Ann Arbor, MI 48105, USA
    Arterioscler Thromb Vasc Biol 20:70-9. 2000
    ....
  2. ncbi Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure
    J T Peterson
    Departments of Cardiovascular Pharmacology, Pfizer Global Research and Development, Ann Arbor, Michigan, USA
    Circulation 103:2303-9. 2001
    ..The present study tested the hypothesis that MMP inhibition would influence LV remodeling and function in developing LV failure...
  3. ncbi A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit
    T M Bocan
    Department of Vascular and Cardiac Diseases, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, MI 48105, USA
    Atherosclerosis 136:203-16. 1998
    ....
  4. ncbi The combined effect of inhibiting both ACAT and HMG-CoA reductase may directly induce atherosclerotic lesion regression
    T M Bocan
    Department of Cardiovascular Therapeutics, Pfizer Global Research and Development, Ann Arbor Laboratories, Pfizer Inc, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Atherosclerosis 157:97-105. 2001
    ....
  5. ncbi HMG-CoA reductase and ACAT inhibitors act synergistically to lower plasma cholesterol and limit atherosclerotic lesion development in the cholesterol-fed rabbit
    T M Bocan
    Department of Vascular and Cardiac Diseases, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, MI 48105, USA
    Atherosclerosis 139:21-30. 1998
    ....
  6. ncbi Molecular sieving and mass spectroscopy reveal enhanced collagen degradation in rabbit atheroma
    J Chen
    Department of Cardiovascular Therapeutics, Pfizer Global Research and Development, Ann Arbor Laboratories, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Atherosclerosis 159:289-95. 2001
    ..Accurate quantification of collagen breakdown products should provide a new relevant end point in the analysis of plaque development and stability...
  7. ncbi Toxicologic effects of a novel acyl-CoA:cholesterol acyltransferase inhibitor in cynomolgus monkeys
    J F Reindel
    Department of Pathology, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, Ann Arbor, Michigan 48105
    Toxicol Pathol 22:510-8. 1994
    ..Sebaceous gland reserve cells were hypertrophic and hyperplastic. Toxicity data from this study indicated that PD 132301-2 at 25-200 mg/kg targeted cholesterol-rich cells of the adrenals, ovaries, and skin adnexa...
  8. ncbi MMP/TIMP expression in spontaneously hypertensive heart failure rats: the effect of ACE- and MMP-inhibition
    H Li
    Department of Cardiovascular Therapeutics, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Cardiovasc Res 46:298-306. 2000
    ....
  9. ncbi Recombinant adenovirus vector mediated expression of lipoprotein (a) [Lp(a)] in rabbit plasma
    R Ramharack
    Department of Cardiovascular Therapeutics, Parke Davis Pharmaceutical Research, Division of Warner Lambert Company, 2800 Plymouth Road, Ann Arbor, MI 48105, USA
    Biochim Biophys Acta 1438:322-8. 1999
    ..Therefore, this system may be suitable for investigating Lp(a)'s role in the development of vascular injury diseases in a rabbit model...